Jiangbo Pharmaceuticals, Inc. engages in the research, development, manufacture, marketing, and sale of pharmaceutical products and health supplements in the People s Republic of China. It offers tablets, capsules, granules, syrups, mixtures, and pillselectuary and oral solutions for Western medical drugs and Chinese herbal-based medical drugs. The company s western pharmaceutical products include Clarithromycin Sustained-release tablets for curing Clarithromycin sensitive microorganism infections; Itopride Hydrochloride granules for curing digestive system-related diseases; Ciprofloxacin Hydrochloride tablets for curing infection caused by bacteria; Paracetamol tablets, which are primarily used for relief of fever, headache, and joint pain; and Felodipine Sustained-released tablets, which are used to treat hypertension and patients with angina. Its Chinese herbal-based pharmaceutical products comprise Baobaole Chewable tablets for gastric cavity aches; Radix Isatidis Disperable tablets for curing virus influenza and sour throat; Kang Gu Sui Yan Pian tablets for treating bone and bone marrow inflammations; Gan Mao Zhi Ke Ke Li, which helps to relieve cold and flu symptoms; Yi Mu Cao Gao that is used to treat dysmenorrhoea, oligminorrhea, and postpartum abdominal pains; Ban Lan Gen Ke Li, a medicine to cure viral influenza; Gan Mao Zhi Ke Tang Jiang, a syrup that helps relieve cold and flu symptoms; and New Compound Foliumisatidis tablets, which address influenza symptoms. Jiangbo Pharmaceuticals sells its products to hospitals, medical institutions, and over the counter retail pharmacies through distributors and salespeople. The company was formerly known as Genesis Pharmaceuticals Enterprises, Inc. and changed its name to Jiangbo Pharmaceuticals, Inc. in April 2009. Jiangbo Pharmaceuticals, Inc. was founded in 2003 and is based in Yantai, the People's Republic of China.